This clinical trial compares the use of standard HPV screening collected by a provider to self collected HPV screening performed by the patient to improve cervical and endometrial cancer screening in patients seeking a gender affirming hysterectomy. This trial also collects information regarding cervical and endometrial cancer screening prior to gender-affirming hysterectomy and the need for screening for transgender people. Providing the option for self collected HPV screening may improve cervical and endometrial cancer screening for patients seeking a gender affirming hysterectomy.
Additional locations may be listed on ClinicalTrials.gov for NCT07075731.
Locations matching your search criteria
United States
Minnesota
Minneapolis
University of Minnesota/Masonic Cancer CenterStatus: Active
Contact: Meredith K Wise
Phone: 612-626-3111
PRIMARY OBJECTIVES:
I. To determine what are the rates of adequate cervical cancer screening and endometrial cancer testing in transgender or gender diverse (TGD) individuals undergoing hysterectomy.
II. To determine what are the rates of undiagnosed cervical and endometrial cancer and their precursors in these individuals.
III. To determine how does introducing the option of human papilloma virus (HPV) self-testing affect the rates of cervical cancer screening and the patient experience in TGD individuals undergoing hysterectomy.
OUTLINE: Patients are assigned to 1 of 2 groups. Group 2 is observational.
GROUP 1: Patients who are not up to date for cervical cancer screening choose between standard cervical cancer screening and HPV self testing. Patients may also decline screening. Patients who are up to date for cervical cancer screening choose between mock HPV self testing for may decline screening.
GROUP 2: Patients complete surveys and may interviews on study.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationUniversity of Minnesota/Masonic Cancer Center
Principal InvestigatorMeredith K Wise
